pre-IPO PHARMA

COMPANY OVERVIEW

Atox Bio is a late stage clinical biotechnology company that develops novel immune modulators for critically ill patients with severe infections.


LOCATION

  • Ness Ziona, , Israel
  • Chapel Hill, NC, USA

  • THERAPEUTIC AREAS

  • Infectious Disease
  • Kidney Disease

  • WEBSITE

    https://www.atoxbio.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    adams-street-partners arix-bioscience lundbeckfondon orbimed sr-one


    PRESS RELEASES


    Dec 10, 2020

    Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection ("Flesh-Eating Disease") USA - English Israel - English


    Jun 18, 2019

    Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI


    Jun 18, 2019

    Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI


    Feb 14, 2019

    Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer


    Feb 14, 2019

    Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer


    For More Press Releases


    Google Analytics Alternative